Aegera Holds First Close

Aegera Therapeutics Inc., a Montreal-based drug developer, has held a Cnd$14 first close on its Series C funding round. VenGrowth led the deal, and was joined by return backers GrowthWorks, Business Development Bank of Canada, Desjardins Venture Capital, Multiple Capital and Solidarity Fund. A second close is scheduled for early 2007. In related news, Aergera has secured a $7 million venture debt facility.